Neratinib (oral tyrosine kinase inhibitor - dual blockade of HER2 and EGFR kinases) for 1 year AFTER neo/adjuvant chemo/trastuzumab - so 2 years total of therapy - improves invasive disease free 5 yr survival vs placebo 90.2% vs 87.7% (absolute 2.5%). Will that translate into overall survival - its not clear. Is that enough of a clinical improvement to warrant a YEAR of therapy...I'm sure that depends on the patient. A safety update showed that, without diarrhea prophylaxis, the most common grade 3 or 4 adverse events in the neratinib vs placebo groups were diarrhea (40% vs 2%), vomiting (3% vs < 1%), and nausea (2% vs < 1%). Serious adverse events occurred in 7% vs 6% (damn placebo pills). http://www.ascopost.com/News/58277?email=c3e93b7a2d24d6b35b681eb833f87b713c5d63c6c79c9f355931dfba8b03af73&utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=7211701
Your De-Identified DNA Can Identify You....
Alcohol Prescriptions.....Hmmmm reminds me of something?
The Breast Care Network identifies community leaders in breast care, and brings them together to advance the global standard of care.
Targeted Medical Education